As an alternative to traditional anticancer therapies, emerging immune checkpoint inhibitors (ICIs) have been shown to be effective in multiple cancer types (12), such as anti-CTLA-4, anti-PD-L1, and anti-PD-1 (Galluzzi et al., 2020; Vaddepally et al., 2020). This evidence concerns the gene CD274 and cancer.